RESUMEN
Tumour progression was monitored in seven multiple myeloma (MM) patients undergoing a novel oral chemotherapy regimen (cyclophosphamide, idarubicin and dexamethasone; CID) followed by early autologous stem cell transplantation (ASCT). Allele-specific oligonucleotide PCR (ASO-PCR) was used to semi-quantitate the number of tumour cells within the peripheral blood (PB) and PB progenitor cell (PBPC) harvests and compared with paraprotein levels and morphological bone marrow (BM) assessments. Tumour cells were detected in the PB of all patients at diagnosis, but decreased in response to CID therapy. All but two of the 22 PBPC collections contained MM cells, the levels of which were statistically correlated with overall clinical response to therapy, but not with individual BM or PB tumour loads prior to mobilisation. We also found no correlation between the day of leucapheresis collection and the number of contaminating MM cells, CD34+ cells or MM cells per CD34+ cell. Regardless of tumour contamination levels in the PBPC collections, the majority of patients demonstrated post-ASCT clearing of circulating MM cells. This study suggests that levels of circulating MM cells may be the best indication of patient response to treatment and argues against the theory of differential mobilisation of tumour cells and CD34+ cells in response to cytokine treatment.
Asunto(s)
Mieloma Múltiple/patología , Mieloma Múltiple/terapia , Células Neoplásicas Circulantes/efectos de los fármacos , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Secuencia de Bases , Recuento de Células , División Celular/efectos de los fármacos , Ciclofosfamida/administración & dosificación , Ciclofosfamida/farmacología , Dexametasona/administración & dosificación , Dexametasona/farmacología , Femenino , Reordenamiento Génico , Movilización de Célula Madre Hematopoyética/efectos adversos , Trasplante de Células Madre Hematopoyéticas , Humanos , Idarrubicina/administración & dosificación , Idarrubicina/farmacología , Cadenas Pesadas de Inmunoglobulina/genética , Cinética , Leucaféresis/normas , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Mieloma Múltiple/genética , Neoplasia Residual/sangre , Neoplasia Residual/diagnóstico , Células Neoplásicas Circulantes/patología , Trasplante AutólogoRESUMEN
Improvement in diagnostic cytogenetic techniques has led to the recognition of an increasing number of leukemia-associated chromosomal translocations and inversions. These genetic lesions frequently are associated with the disruption of putative transcription factors and the production of hybrid transcripts that are implicated in leukemogenesis. Epidemiologic evidence suggests that some, but not all, individuals with a history of gamma-irradiation exposure are at increased risk of developing chronic myeloid leukemia (CML). CML is characterized by the Philadelphia chromosome and transcription of the resulting hybrid BCR-ABL gene. Utilizing the leukemia-associated BCR-ABL p210 transcript as a marker, we sought differences in the induction of illegitimate genetic recombination following high-dose gamma-irradiation of karyotypically normal lymphoblastoid cell lines (LCL) derived from individuals with and without a history of myeloid leukemias. Six LCL [4 leukemia patient derived [2 acute myeloid leukemia and 2 CML] and 2 from normal individuals were analyzed with reverse transcriptase polymerase chain reaction for BCR-ABL under stringent conditions following exposure to 0, 50, or 100 Gy of LET gamma-irradiation delivered via a Varian linear accelerator at 4 MV. Transcripts identical to disease-associated b2a2 and b3a2 transcripts were detected both spontaneously (background illegitimate genetic recombination) and following gamma-irradiation. Background BCR-ABL positivity was demonstrable in 4 of the 6 LCL, with no significant difference in detection between leukemic- and nonleukemic-derived LCL. Overall, increasing gamma-irradiation dose resulted in an increased frequency of BCR-ABL transcript detection (0 Gy vs 50 Gy vs 100 Gy,p = 0.0023, Chi-square test). Within the leukemic- but not the nonleukemic-derived LCL there was significantly greater BCR-ABL positivity after gamma-irradiation compared to unirradiated equivalents. Furthermore, the BCR-ABL positivity of both the AML- and CML-derived LCL after gamma-irradiation was significantly greater than that of the nonleukemic-derived LCL after gamma-irradiation. We speculate that this difference in the detection of illegitimate after gamma-irradiation recombination may be due to aberrant DNA double strand break repair mechanisms in individuals predisposed to the development of myeloid leukemias.
Asunto(s)
Reparación del ADN , Regulación Leucémica de la Expresión Génica/efectos de la radiación , Leucemia Mieloide/patología , Linfocitos/efectos de la radiación , Recombinación Genética/efectos de la radiación , Enfermedad Aguda , Adulto , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/efectos de la radiación , Células Cultivadas , Cromosomas Humanos/efectos de la radiación , Daño del ADN , Femenino , Proteínas de Fusión bcr-abl/genética , Rayos gamma , Genes abl/efectos de la radiación , Predisposición Genética a la Enfermedad , Humanos , Cariotipificación , Leucemia Mielógena Crónica BCR-ABL Positiva/etiología , Leucemia Mielógena Crónica BCR-ABL Positiva/genética , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Leucemia Mieloide/etiología , Leucemia Mieloide/genética , Transferencia Lineal de Energía , Linfocitos/metabolismo , Persona de Mediana Edad , Neoplasias Inducidas por Radiación/etiología , Neoplasias Inducidas por Radiación/genética , Células Madre Neoplásicas/metabolismo , Células Madre Neoplásicas/efectos de la radiación , Aceleradores de Partículas , Reacción en Cadena de la Polimerasa , Riesgo , Células Tumorales Cultivadas/efectos de la radiaciónRESUMEN
A 47-year-old man with a 2-year history of Philadelphia chromosome-positive chronic phase (CP) chronic myeloid leukaemia (CML) underwent autologous PBSCT. During the period of haemopoietic reconstitution he underwent five leucapheretic (LP) harvests yielding a total of 2.6 x 10(6)/kg CD34+ cells. Cytogenetic analyses revealed 94, 83, 83, 96 and 85% Ph negativity respectively for the five harvests. RT-PCR analyses for BCR-ABL performed on randomly picked CFU-GM from the five LP products were negative in all cases. These observations suggest that the majority of harvested cells, including the more primitive clonogenic cells, were BCR-ABL (Ph) negative and presumably were not part of the leukaemic clone. These findings support the notion that autologous PBSCT in CML whilst serving as a therapeutic manoeuvre may also facilitate the collection of non-leukaemic progenitor cells for further transplantation procedures.